Allergan, Plc

Uncategorized
Uncategorized
back to directoryBack to Directory

Related Posts:

ALLERGAN: Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients
ALLERGAN: Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients

March 5, 2020

Allergan continues five ongoing Phase 3 studies with DURYSTA™ to support further potential FDA label enhancement and rest of the world approvals

Read more →

Trending

BAYER: U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Prescribing Information
LOCATE BIO: CognitOss Granted FDA Breakthrough Device Designation
NORTHSTAR MEDICAL RADIOISOTOPES: Announces FDA Approval for Enhanced U.S. Mo-99 Radioisotope Production Capacity
KING & SPALDING: FDA and Life Sciences Team Adds Partner in Washington
FUNCTIONAL NEUROMODULATION: Announces Breakthrough Device Designation from the U.S. FDA for Deep Brain Stimulation for Alzheimer’s Disease
ULTROMICS: Receives Fda Clearance for a First-of-kind Solution in Echocardiography to Help Clinicians Diagnose Disease

The Weekly Newsletter

Sign-up for the Weekly Newsletter from FDA Reporter.